MX2015003352A - Extracto de saliva entera de sanguijuela. - Google Patents

Extracto de saliva entera de sanguijuela.

Info

Publication number
MX2015003352A
MX2015003352A MX2015003352A MX2015003352A MX2015003352A MX 2015003352 A MX2015003352 A MX 2015003352A MX 2015003352 A MX2015003352 A MX 2015003352A MX 2015003352 A MX2015003352 A MX 2015003352A MX 2015003352 A MX2015003352 A MX 2015003352A
Authority
MX
Mexico
Prior art keywords
leech
treat
whole
extract
methods
Prior art date
Application number
MX2015003352A
Other languages
English (en)
Other versions
MX362375B (es
Inventor
Ahmed Merzouk
Abbas Mohammad Ghawi
Abdualrahman M Abdualkader
Mohamed Alaama
Original Assignee
Biopep Solutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biopep Solutions Inc filed Critical Biopep Solutions Inc
Publication of MX2015003352A publication Critical patent/MX2015003352A/es
Publication of MX362375B publication Critical patent/MX362375B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Agronomy & Crop Science (AREA)
  • Biotechnology (AREA)

Abstract

Se proveen métodos para aislar y usar un extracto de saliva entera de sanguijuela; los métodos pueden incluir alimentar a una sanguijuela con un agente fagoestimulador; inducir regurgitación en la sanguijuela, la inducción incluyendo poner la sanguijuela en un medio que tiene una temperatura menor de aproximadamente 0°C; y recolectar la saliva entera no refinada de la regurgitación de la sanguijuela fría; los métodos pueden incluir revitalizar la sanguijuela calentándola a una temperatura que varía de aproximadamente 5°C a aproximadamente 40°C; también se proveen extractos liofilizados estables de saliva entera de sanguijuela, el extracto teniendo una actividad estable cuando se almacena para usarse, a una temperatura menor de aproximadamente 20°C, el extracto manteniendo por lo menos 70% de la actividad durante por lo menos 6 meses; los extractos se pueden usar para tratar tumores sólidos, tratar tumores líquidos, tratar la diabetes, tratar una enfermedad viral, tratar una enfermedad parasitaria, tratar una enfermedad bacteriana, o servir como un antioxidante.
MX2015003352A 2012-09-17 2013-09-17 Extracto de saliva entera de sanguijuela. MX362375B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261701735P 2012-09-17 2012-09-17
US13/624,847 US8685462B1 (en) 2012-09-17 2012-09-21 Whole, leech saliva product and applications thereof
PCT/IB2013/002848 WO2014049447A2 (en) 2012-09-17 2013-09-17 A whole, leech saliva extract

Publications (2)

Publication Number Publication Date
MX2015003352A true MX2015003352A (es) 2015-10-22
MX362375B MX362375B (es) 2019-01-14

Family

ID=48876315

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003352A MX362375B (es) 2012-09-17 2013-09-17 Extracto de saliva entera de sanguijuela.

Country Status (10)

Country Link
US (17) US8790711B2 (es)
EP (1) EP2895178B1 (es)
JP (1) JP6220398B2 (es)
CN (1) CN104837495A (es)
AU (1) AU2013322269B2 (es)
CA (1) CA2882533A1 (es)
ES (1) ES2710126T3 (es)
IN (1) IN2015DN02729A (es)
MX (1) MX362375B (es)
WO (1) WO2014049447A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8790711B2 (en) 2012-09-17 2014-07-29 Biopep Solutions, Inc. Treating diabetes with a whole, leech saliva extract
KR101341289B1 (ko) * 2013-07-09 2013-12-12 한선대 거머리 타액의 채취방법
CN104151425B (zh) * 2014-08-15 2017-02-08 周维海 一种天然水蛭素的规模化生产方法
CN104365560A (zh) * 2014-10-29 2015-02-25 颍上县永祥旱粮研究所 一种水蛭的养殖方法
CN105594666B (zh) * 2015-12-25 2020-04-03 贵州信邦制药股份有限公司 一种快速增加水蛭抗凝血酶活性的养殖方法
CN105418756B (zh) * 2015-12-25 2018-12-21 汤浩强 一种水蛭唾液重复提取的方法
CN108210523A (zh) * 2016-12-09 2018-06-29 江苏小潘园生态农业科技发展有限公司 一种水蛭酒的制作方法
CN107129962B (zh) * 2017-05-18 2019-03-05 中国计量大学 一种日本医蛭唾液腺细胞的原代培养方法
CN107519036A (zh) * 2017-09-06 2017-12-29 深圳肽之妃科技有限公司 一种含多肽的妊娠纹喷剂及其制备方法
CN107796183A (zh) * 2017-11-17 2018-03-13 广西远程水蛭养殖有限公司 水蛭干燥方法
CN109528773A (zh) * 2019-01-15 2019-03-29 昆明学院 水蛭唾液在制备镇痛药物中的应用
CN109662984B (zh) * 2019-02-13 2022-07-26 昆明医科大学 臭灵丹和迷迭香提取物在抗ⅱ型登革病毒药物中的应用
US10787338B1 (en) 2019-08-30 2020-09-29 Blazing Spools LLC Spool device and related methods
CN112915106A (zh) * 2021-02-05 2021-06-08 张虎山 一种肿瘤免疫微环境调控剂的制备及其应用
CN113577821B (zh) * 2021-07-07 2022-08-30 三峡大学 一种活体水蛭素的重复提取装置及方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588587A (en) 1983-03-01 1986-05-13 Pennsylvania Hospital Method of treatment to inhibit metastasis
WO1987000860A1 (en) 1985-08-10 1987-02-12 Biopharm (Uk) Limited Collagen-specific enzyme with platelet aggregation inhibition properties
US4832849A (en) 1988-06-16 1989-05-23 Merrell Dow Pharmaceuticals Inc. Extraction and purification of an anticoagulant principle from the south american leech, haementeria ghilianii
IL86857A (en) * 1988-06-24 1994-04-12 Yissum Res Dev Co Platelet-aggregating inhibitory agents from leech saliva and pharmaceutical preparations containing the same
GB8826428D0 (en) * 1988-11-11 1988-12-14 Biopharm Ltd Antithrombin
KR0185973B1 (ko) 1989-06-20 1999-05-01 게리 디. 스트리트 남미의 거머리인 헤멘테리아 길리아니로부터의 항전이 물질 길란텐
ZA904622B (en) 1989-06-20 1991-03-27 Merrell Dow Pharma Ghilanten:antimetastatic principle from the south american leech,haementeria ghilanii
DE4103649A1 (de) 1991-02-07 1992-08-13 Basf Ag Neue antikoagulatorisch wirksame peptide
AU659432B2 (en) 1991-03-08 1995-05-18 Novartis Ag A method for the inhibition or prevention of tumor cell metastasis with hirudin
DE4209110A1 (de) 1991-11-26 1993-05-27 Basf Ag Neue thrombininhibitorische proteine aus landblutegeln
DE4234921A1 (de) 1992-10-16 1994-04-21 Basf Ag Neues, die Gerinnungszeit des Blutes verlängerndes Protein aus dem Landblutegel Haemadipsa sylestris
KR960701649A (ko) 1993-04-09 1996-03-28 심파쓰 Xa인자 억제활성을 가진 신규 폴리펩티드
GB9309509D0 (en) 1993-05-07 1993-06-23 Merck Patent Gmbh Thrombin inhibitors
WO1995004750A1 (en) 1993-08-09 1995-02-16 Athena Neurosciences, Inc. Tick derived protease inhibitor
ATE299707T1 (de) * 1995-11-13 2005-08-15 Vitaleech Bioscience N V Antivirale isolate von blutegeln
US6610292B2 (en) 1995-11-22 2003-08-26 Ista Pharmaceuticals, Inc. Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
US5866120A (en) 1995-11-22 1999-02-02 Advanced Corneal Systems, Inc. Method for accelerating clearance of hemorrhagic blood from the vitreous humor with hyaluronidase
EP0875564A1 (en) 1997-05-02 1998-11-04 Gerard Voerman Biologically active extract from the leech 'Limnatis nilotica'
SE512633C2 (sv) 1997-07-09 2000-04-17 Cecilia Johnsson Användning av hyaluronidas för reduktion av inflammatoriska cellinfiltrat
DK1185666T3 (da) 1999-06-12 2006-07-03 Merck Patent Gmbh Hyaluronidase fra Hirudinaria manillensis, isolering, oprensning og rekombinant fremgangsmåde til fremstilling
KR20040049830A (ko) 2001-07-09 2004-06-12 애프톤 코포레이션 간, 폐 및 식도의 암 및 전암 상태의 치료 및 예방
CN1273012C (zh) * 2003-01-15 2006-09-06 周维海 从菲牛蛭活体中提取天然水蛭素的方法
CN101230086A (zh) * 2007-01-22 2008-07-30 广东海洋大学 一种以菲牛蛭唾液为原材料的水蛭素生产工艺
WO2009018640A1 (en) 2007-08-07 2009-02-12 Universidade Federal De São Paulo Unifesp Use of platelet aggregation and coagulation inhibitors isolated from bauhinia sp.
WO2009120186A1 (en) * 2008-03-24 2009-10-01 Carolus Therapeutics, Inc. Methods and compositions for treating atherosclerosis and related conditions
EP2316465A1 (en) 2009-10-15 2011-05-04 Centre National De La Recherche Scientifique Use of extract of leeches' saliva as anti-bacterial agent for the manufacture of different compositons
CN102258771A (zh) 2011-07-13 2011-11-30 中国药科大学 重组水蛭素在防治糖尿病性白内障中的应用
US8790711B2 (en) 2012-09-17 2014-07-29 Biopep Solutions, Inc. Treating diabetes with a whole, leech saliva extract
CN102964446B (zh) * 2012-11-28 2014-08-13 周维官 一种吸血水蛭活体多次提取天然水蛭素方法

Also Published As

Publication number Publication date
US20160120913A1 (en) 2016-05-05
US9597361B2 (en) 2017-03-21
US20140079799A1 (en) 2014-03-20
JP6220398B2 (ja) 2017-10-25
US9265802B2 (en) 2016-02-23
CN104837495A (zh) 2015-08-12
MX362375B (es) 2019-01-14
US8501241B1 (en) 2013-08-06
US20160120914A1 (en) 2016-05-05
US8932642B2 (en) 2015-01-13
US20150086645A1 (en) 2015-03-26
US20140356448A1 (en) 2014-12-04
WO2014049447A2 (en) 2014-04-03
US20140363518A1 (en) 2014-12-11
EP2895178A4 (en) 2016-05-25
AU2013322269B2 (en) 2018-05-31
EP2895178B1 (en) 2018-11-07
US20140079798A1 (en) 2014-03-20
US10064897B2 (en) 2018-09-04
US20160331790A1 (en) 2016-11-17
US9144587B2 (en) 2015-09-29
AU2013322269A1 (en) 2015-03-05
WO2014049447A3 (en) 2014-06-19
US20160331789A1 (en) 2016-11-17
US8790711B2 (en) 2014-07-29
US8784896B2 (en) 2014-07-22
US20170239301A1 (en) 2017-08-24
ES2710126T3 (es) 2019-04-23
US20150359826A1 (en) 2015-12-17
US9017732B1 (en) 2015-04-28
JP2015528491A (ja) 2015-09-28
US9480720B1 (en) 2016-11-01
US9265803B2 (en) 2016-02-23
US20140079800A1 (en) 2014-03-20
US20150196607A1 (en) 2015-07-16
EP2895178A2 (en) 2015-07-22
IN2015DN02729A (es) 2015-09-04
US9005667B1 (en) 2015-04-14
US9433648B2 (en) 2016-09-06
US20150359825A1 (en) 2015-12-17
US8962034B2 (en) 2015-02-24
CA2882533A1 (en) 2014-04-03
US8685462B1 (en) 2014-04-01
US9149498B2 (en) 2015-10-06
US20150099006A1 (en) 2015-04-09
US20150182562A1 (en) 2015-07-02
US9433649B2 (en) 2016-09-06

Similar Documents

Publication Publication Date Title
MX2015003352A (es) Extracto de saliva entera de sanguijuela.
MX2016001587A (es) Inhibidores de kdm1a para el tratamiento de enfermedades.
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
NZ702663A (en) Nuclear transport modulators and uses thereof
MA37400A1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
JO3776B1 (ar) التركيبات الصيدلانية لمثبط CDK4 / 6 ومثبط B-Raf
MX2019008122A (es) Derivados de aminas heterociclicas que inhiben la transduccion de se?al mediada por cinasa asociada con el receptor de interleucina-1.
SG10201803862UA (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
MX2013004061A (es) Analogos de ciclosporina.
BR112012028711A2 (pt) métodos para a fabricação de uma emulsão de óleo em água, para a preparação de um kit de vacina e para redestilação de uma composição compreendendo 99% de esqualeno ou mais, assim como emulsão de óleo em água e kit
UA112549C2 (uk) Частинки на основі поліакрилату, що містять активну сполуку
CL2014003325A1 (es) Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer
MX363270B (es) Composiciones y metodos para inhibir la polimerasa viral.
MX2013004062A (es) Analogos de ciclosporina.
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
IN2014MN02269A (es)
WO2014165723A3 (en) Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells
MX343517B (es) 2,4 pirimidinadiaminas sustituidas para su uso en lupus discoide.
WO2011091154A3 (en) Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
WO2014100857A8 (en) Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
MX2014006574A (es) Formulaciones de acamprosato, metodos de uso de las mismas, y combinaciones que comprenden las mismas.
WO2012108748A3 (ko) 합환피 추출물을 포함하는 뇌암 치료용 조성물 및 화장료 조성물

Legal Events

Date Code Title Description
FG Grant or registration